Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04462666
Other study ID # 2020024
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date July 1, 2020
Est. completion date August 31, 2023

Study information

Verified date July 2020
Source Shanghai Yueyang Integrated Medicine Hospital
Contact Bin Li
Phone 0086-021-55981301
Email 18930568129@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We designed this study as a double-blind, randomized, controlled clinical trial. The aim of the study is to evaluate the clinical efficacy, safety and control of recurrence rate of acute gouty arthritis


Description:

Gout is a recurrent chronic inflammatory disease caused by monosodium urate (MSU) crystal . Acute gouty arthritis (GA) is the most common first symptom of gout. With the progress of the disease, the frequency of acute attack increases, and joint destruction may occur. The prevalence of hyperuricemia in China was about 13.3%, and the pooled prevalence of gout was 1.1%. Repeated attacks of GA seriously affect the quality of life, resulting in huge economic costs and mental stress. Due to inadequate prevention and treatment, the target of healing gout is often not achieved. In GA, TCM has shown satisfactory therapeutic effect with less adverse effects and minimal toxicity. Huzhang granule (HZG), a Chinese herbal prescription, is a compound preparation with twelve ingredients which has been used in the clinical treatment of gout for over 30 years at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of TCM.Therefore,this double-blind, randomized, controlled clinical trial. will provide high-quality clinical evidences for evaluating the clinical efficacy, safety and control of recurrence rate of Huzhang granule ,a representative prescription for the treatment of acute gouty arthritis , in the treatment of GA.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 267
Est. completion date August 31, 2023
Est. primary completion date July 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Diagnosis of acute gout arthritis as defined by the American College of Rheumatology 1977 preliminary criteria;

- Male or non-pregnant, non-nursing female;

- 18-70 years of age;

- Gout attack less =48 hours;

- In the week before this observation, non-steroidal anti-inflammatory drugs and analgesic drugs and drugs affecting uric acid metabolism were not taken;

- Subjects capable of giving informed consent;

Exclusion Criteria:

- failing to meet the diagnostic criteria;

- Evidence of uncontrolled concomitant cardiovascular, nervous system,hepatic or gastrointestinal disease. Potential participants who have active concomitant disease can only be eligible after discussion and agreement with the treating medical team;

- the patient is in critical condition and it is difficult to evaluate the effectiveness and safety of the clinical observation;

- severe deformity, stiffness and labor loss of patients with advanced arthritis;

- known allergic to the drug used in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Huzhang granule
Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
Etoricoxib
take one capsule per day in the morning, at approximately 30 minutes after the meal.
Huzhang granule Placebo
Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
Etoricoxib Placebo
take one capsule per day in the morning, at approximately 30 minutes after the meal.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Yueyang Integrated Medicine Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Analogue Score (VAS) Visual Analogue Score is an often-used tool to measure subjective phenomena, which has shown good reliability and validity in terms of assessment of pain. In the clinical study of acute gout attack,it can be used as a tool to measure the degree of pain from 0 to 100 mm (with 0 being no pain and 100 being maximum pain) Up to 5 days after treatment
Secondary Likert scales for the assessment of joint tenderness and swelling Likert scales for the assessment of joint tenderness and swelling is evaluate the inflammatory response and the degree of injury of the joint.Scores range from 1-5, a higher score indicating a severe symptoms on a participant's joint Up to 5 days after treatment
Secondary symptom relief time Symptom relief time is the time when joint pain feels relieved Up to 5 days after treatment
Secondary 36-Item Short Form Survey 36-Item Short Form Survey is a health status profile originally designed to measure eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions.
Scoring the 36-Item Health Survey is a two-step process. First, precoded numeric values are recoded per the scoring key in a given table. Note that all items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In step 2, items in the same scale are averaged together to create the 8 scale scores. another lists the items averaged together to create each scale. Items that are left blank (missing data) are not taken into account when calculating
Up to 5 days after treatment
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06068478 - A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis Phase 3
Recruiting NCT01867840 - Role of ASICs in Human Inflammatory Pain N/A
Completed NCT00927810 - Long Term Study of Canakinumab (ACZ885) in Patients With Gout Phase 2
Completed NCT05332795 - The Impact of Metformin on the Outcome of Gouty Arthritis in a Cohort of Egyptian Gouty Patients. N/A
Completed NCT05964946 - Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France
Terminated NCT01362608 - Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective Phase 3
Completed NCT01626235 - AMPED Outcomes Registry of Post-ED Pain Management N/A
Recruiting NCT05658575 - Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Phase 2/Phase 3